{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:09:16Z","timestamp":1769224156052,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011259","name":"FP7 International Cooperation","doi-asserted-by":"publisher","award":["305507"],"award-info":[{"award-number":["305507"]}],"id":[{"id":"10.13039\/100011259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The \u201cHeart OMics in AGEing\u201d (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardiac remodelling in an at risk population, potentially slowing the progression towards HF. We compared the proteomic profile of patients with and without diabetes among patients at risk for HF in the HOMAGE trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Protein biomarkers (n\u2009=\u2009276) from the Olink\u00aeProseek-Multiplex cardiovascular and inflammation panels were measured in plasma collected at baseline and 9 months (or last visit) from HOMAGE trial participants including 217 patients with, and 310 without, diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-one biomarkers were increased and five decreased in patients with diabetes compared to non-diabetics at baseline. The markers clustered mainly within inflammatory and proteolytic pathways, with granulin as the key-hub, as revealed by knowledge-induced network and subsequent gene enrichment analysis. Treatment with spironolactone in diabetic patients did not lead to large changes in biomarkers. The effects of spironolactone on NTproBNP, fibrosis biomarkers and echocardiographic measures of diastolic function were similar in patients with and without diabetes (all interaction analyses p\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Amongst patients at risk for HF, those with diabetes have higher plasma concentrations of proteins involved in inflammation and proteolysis. Diabetes does not influence the effects of spironolactone on the proteomic profile, and spironolactone produced anti-fibrotic, anti-remodelling, blood pressure and natriuretic peptide lowering effects regardless of diabetes status.\u00a0<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>\u00a0NCT02556450.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-021-01357-9","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:45:32Z","timestamp":1628610332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct02556450","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-1298","authenticated-orcid":false,"given":"Job A. J.","family":"Verdonschot","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[]},{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"additional","affiliation":[]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[]},{"given":"Franco","family":"Cosmi","sequence":"additional","affiliation":[]},{"given":"Joe","family":"Cuthbert","sequence":"additional","affiliation":[]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[]},{"given":"Beatrice","family":"Mariottoni","sequence":"additional","affiliation":[]},{"given":"Johannes","family":"Petutschnigg","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[]},{"given":"John G. F.","family":"Cleland","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]},{"given":"Stephane R. B.","family":"Heymans","sequence":"additional","affiliation":[]},{"name":"HOMAGE \u201cHeart Omics in AGEing\u201d consortium","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"issue":"5","key":"1357_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0735-1097(03)00856-8","volume":"42","author":"M Domanski","year":"2003","unstructured":"Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42(5):914\u201322.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1357_CR2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00125-019-4960-8","volume":"62","author":"K Beijer","year":"2019","unstructured":"Beijer K, Nowak C, Sundstr\u00f6m J, \u00c4rnl\u00f6v J, Fall T, Lind L. In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study. Diabetologia. 2019;62(11):1998\u20132006.","journal-title":"Diabetologia"},{"issue":"1","key":"1357_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41598-018-36512-y","volume":"9","author":"J Molvin","year":"2019","unstructured":"Molvin J, Pareek M, Jujic A, Melander O, R\u00e5stam L, Lindblad U, Daka B, Le\u00f3sd\u00f3ttir M, Nilsson PM, Olsen MH, et al. Using a targeted proteomics chip to explore pathophysiological pathways for incident diabetes\u2014the Malm\u00f6 preventive project. Sci Rep. 2019;9(1):272.","journal-title":"Sci Rep"},{"issue":"3","key":"1357_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jchf.2019.11.005","volume":"8","author":"J Tromp","year":"2020","unstructured":"Tromp J, Voors AA, Sharma A, Ferreira JP, Ouwerkerk W, Hillege HL, Gomez KA, Dickstein K, Anker SD, Metra M, et al. Distinct pathological pathways in patients with heart failure and diabetes. JACC Heart Fail. 2020;8(3):234\u201342.","journal-title":"JACC Heart Fail"},{"issue":"9","key":"1357_CR5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ejhf.1716","volume":"22","author":"P Pellicori","year":"2020","unstructured":"Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, et al. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. Eur J Heart Fail. 2020;22(9):1711\u201323.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1357_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2020","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca H-P, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2020;42(6):684\u201396.","journal-title":"Eur Heart J"},{"issue":"10","key":"1357_CR7","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","volume":"47","author":"JI Davies","year":"2004","unstructured":"Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004;47(10):1687\u201394.","journal-title":"Diabetologia"},{"issue":"5","key":"1357_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","volume":"160","author":"M Yamaji","year":"2010","unstructured":"Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure. Am Heart J. 2010;160(5):915\u201321.","journal-title":"Am Heart J"},{"issue":"4","key":"1357_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","volume":"9","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca H-P, Clark AL, Cosmi F, Cuthbert J, et al. Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Heart Fail. 2021;9(4):268\u201377.","journal-title":"JACC Heart Fail"},{"issue":"3","key":"1357_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.RES.0000207919.83894.9d","volume":"98","author":"T Ago","year":"2006","unstructured":"Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res. 2006;98(3):294\u20137.","journal-title":"Circ Res"},{"issue":"10","key":"1357_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jchf.2017.07.013","volume":"5","author":"A Sharma","year":"2017","unstructured":"Sharma A, Stevens SR, Lucas J, Fiuzat M, Adams KF, Whellan DJ, Donahue MP, Kitzman DW, Pi\u00f1a IL, Zannad F, et al. Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study. JACC Heart Fail. 2017;5(10):724\u201334.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"1357_CR12","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s42255-019-0146-4","volume":"1","author":"EA Day","year":"2019","unstructured":"Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, Gutgesell RM, Lu R, Raphenya AR, Kabiri M, McArthur AG, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019;1(12):1202\u20138.","journal-title":"Nat Metab"},{"issue":"7795","key":"1357_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, Cimino I, Yang M, Welsh P, Virtue S, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444\u20138.","journal-title":"Nature"},{"issue":"6","key":"1357_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.amjcard.2014.06.020","volume":"114","author":"A Dominguez-Rodriguez","year":"2014","unstructured":"Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2014;114(6):890\u20134.","journal-title":"Am J Cardiol"},{"issue":"10","key":"1357_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","volume":"72","author":"J Tromp","year":"2018","unstructured":"Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, et al. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2018;72(10):1081\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1357_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41591-019-0358-x","volume":"25","author":"X Feng","year":"2019","unstructured":"Feng X, Guan D, Auen T, Choi JW, Salazar Hern\u00e1ndez MA, Lee J, Chun H, Faruk F, Kaplun E, Herbert Z, et al. IL1R1 is required for celastrol\u2019s leptin-sensitization and antiobesity effects. Nat Med. 2019;25(4):575\u201382.","journal-title":"Nat Med"},{"issue":"4","key":"1357_CR17","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.cell.2016.10.015","volume":"167","author":"J Liu","year":"2016","unstructured":"Liu J, Ibi D, Taniguchi K, Lee J, Herrema H, Akosman B, Mucka P, Salazar Hernandez MA, Uyar MF, Park SW, et al. Inflammation improves glucose homeostasis through IKK\u03b2-XBP1s interaction. Cell. 2016;167(4):1052-1066.e1018.","journal-title":"Cell"},{"issue":"1","key":"1357_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cmet.2014.05.005","volume":"20","author":"I Wernstedt Asterholm","year":"2014","unstructured":"Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, Scherer PE. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014;20(1):103\u201318.","journal-title":"Cell Metab"},{"issue":"11","key":"1357_CR19","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1002\/ejhf.1674","volume":"22","author":"MF Hoes","year":"2019","unstructured":"Hoes MF, Tromp J, Ouwerkerk W, Bomer N, Oberdorf-Maass SU, Samani NJ, Ng LL, Lang CC, van der Harst P, Hillege H, et al. The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. Eur J Heart Fail. 2019;22(11):2102\u201311.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"1357_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00125-019-05025-2","volume":"63","author":"L Ding","year":"2020","unstructured":"Ding L, Goossens GH, Oligschlaeger Y, Houben T, Blaak EE, Shiri-Sverdlov R. Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans. Diabetologia. 2020;63(2):374\u201384.","journal-title":"Diabetologia"},{"issue":"3","key":"1357_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4161\/adip.24144","volume":"2","author":"A Eguchi","year":"2013","unstructured":"Eguchi A, Feldstein AE. Lysosomal cathepsin D contributes to cell death during adipocyte hypertrophy. Adipocyte. 2013;2(3):170\u20135.","journal-title":"Adipocyte"},{"issue":"6","key":"1357_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/pedi.13062","volume":"21","author":"JB Tryggestad","year":"2020","unstructured":"Tryggestad JB, Shah RD, Braffett BH, Bacha F, Gidding SS, Gubitosi-Klug RA, Shah AS, Urbina EM, Levitt Katz LE. Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the treatment options for type 2 diabetes in adolescent and youth study. Pediatr Diabetes. 2020;21(6):923\u201331.","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"1357_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/0004563216640001","volume":"54","author":"AE Zemlin","year":"2017","unstructured":"Zemlin AE, Matsha TE, Kengne AP, Hon GM, Erasmus RT. Correlation of E-selectin concentrations with carotid intima-media thickness and cardio-metabolic profile of mixed ancestry South Africans: a cross-sectional study. Ann Clin Biochem. 2017;54(1):92\u2013100.","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"1357_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s004390000325","volume":"107","author":"C Sass","year":"2000","unstructured":"Sass C, Pallaud C, Zannad F, Visvikis S. Relationship between E-selectin L\/F554 polymorphism and blood pressure in the Stanislas cohort. Hum Genet. 2000;107(1):58\u201361.","journal-title":"Hum Genet"},{"issue":"1","key":"1357_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cmet.2011.12.002","volume":"15","author":"T Matsubara","year":"2012","unstructured":"Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, Tamori Y, Yokoi N, Watanabe M, Matsuo E, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 2012;15(1):38\u201350.","journal-title":"Cell Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01357-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:52:42Z","timestamp":1628610762000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01357-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1357"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01357-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"assertion":[{"value":"3 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by all relevant ethics committees and regulatory bodies. All participants provided written informed consent prior to study-specific procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There is no data of individual persons included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant conflicts of interest to disclose with regards to the content of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}